Research Projects & Grants

For Profit Organization

  • A Phase I, Randomized, Open-Label, Active Controlled, Multi-Center Pilot Study to Compare Reference to Reference Pharmacodynamics of BOTOX® (onabotulinumtoxinA) in Healthy Subjects. Protocol: MR 103A-0I-IPS-1001. lnformed Consent Form Version Dated 25 November 2022., Role: Investigational Pharmacist, Mylan Pharmaceuticals, (11/2023 - 03/2024) Status: Completed
  • An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Repeat Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia. Protocol Number: ABP-19002, Role: Investigational Pharmacist, Aeon Biopharma, (12/2022 - 12/2023) Status: Completed
  • A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia. Protocol Number: ABP-19000, Role: Investigator, Aeon Biopharma, (06/2022 - 06/2023) Status: Completed
  • A phase 3, open-label study of the safety, efficacy, and tolerability of apomorphine administered by continuous subcutaneous infusion in advanced Parkinson's disease patients with unsatisfactory control on available therapy, Role: Investigator, U.S. World Meds, (11/2021 - 11/2022) Status: Completed
  • A Phase 3, open-label, multi-center trial to evaluate the long-term safety and efficacy of repeat treatment of DaxibotulinumtoxinA for injection in adult with isolated cervical dystonia (ASPEN-OLS). Protocol: 1720304, Role: Investigator, Revance Therapeutics, Inc., (04/2021 - 04/2022) Status: Completed
  • A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multi-center trial to evaluate the efficacy and safety of a single treatment of DaxibotulinumtoxinA for injection in adults with isolated cervical dystonia (ASPEN-1). Protocol: 1720302, Role: Investigator, Revance Therapeutics, Inc., (11/2019 - 11/2020) Status: Completed
  • A phase III multi-center randomized double-bind double-dummy active-controlled study comparing the efficacy and safety of gastric retentive controlled release accordion pill™ carbidopa/levodopa (AP-CD/LD) to immediate release CD/LD in fluctuating Parkinson's Disease patients Protocol Number: IN 11004, Role: Investigator, Intec Pharma Ltd., (04/2019 - 04/2020) Status: Completed
  • Evaluation of the safety and pharmacodynamic effect of AGN-151607 by measuring the compound muscle action potential (CMAP) of the extensor digitorum brevis ( EDB) muscle following a single injection in healthy subjects. Protocol 1925-101-008, dated 18 August 2017. Informed consent form version dated 30 August 2017, Role: Investigator, Allergan Inc., (08/2018 - 08/2019) Status: Completed
  • A Multicenter, Interventional, Post-marketing, Randomized, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity. Protocol: CLIN-52120-452, Role: Investigational Pharmacist, Ipsen Pharma SAS, (11/2024 - 11/2025) Status: Approved

Internal

  • Evaluation of safety in patients receiving quetiapine and pimavanserin for Parkinson Disease related psychosis, Role: PI, LLU Dept. of Pharmacy Practice, (07/2023) Status: Approved
  • Access to Opicapone and Istradefylline in adult patients with Parkinson's disease, Role: PI, LLU Dept. of Pharmacy Practice, (10/2022) Status: Approved
  • Evaluation of Risk Factors for Development of Drug-Induced Parkinsonism (DIP), Role: PI, LLU Dept. of Pharmacy Practice, (10/2022) Status: Approved
  • Role of lithium in depression and suicidal ideation in end stage renal disease patients, Role: Investigator, LLU Dept. of Pharmacy Practice, (07/2021) Status: Approved
  • A retrospective study to investigate the effect of VMAT-2 inhibitors on Tardive Dyskinesia, Role: PI, LLU Dept. of Pharmacy Practice, (06/2021) Status: Approved
  • Role of lithium in depression and suicidal ideation in end stage renal disease patients, Role: PD/PI, LLU - GRASP, (01/2021 - 06/2025) Status: Awarded
  • The effect of the COVID-19 pandemic on the prescribing practices of opioid and opioid use, Role: PI, LLU Dept. of Pharmacy Practice, (09/2020) Status: Approved
  • Impact of naloxone mandate on naloxone prescribing for reversal of opioid overdose, Role: PI, LLU Dept. of Pharmacy Practice, (12/2019) Status: Approved
  • The effect of the CURES mandate on prescribing practices of class II - IV controlled substances and naloxone, Role: Investigator, LLU Dept. of Pharmacy Practice, (12/2019 - 07/2023) Status: Completed
  • Combination therapy of Opioids with Tricyclic Antidepressants (TCAs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Role: PI, LLU School of Pharmacy, (06/2019) Status: Approved
  • The Evaluation of opioid and opioid use disorder medication prescribing amongst Latinx patients, Role: PI, LLU Dept. of Pharmacy Practice, (10/2024) Status: Approved
  • Correlation of spirituality and Parkinson's disease, Role: Investigational Pharmacist, LLU Dept. of Neurology, (05/2023) Status: Approved

Non-Profit Organization

  • An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability Of 24-Hour Daily Exposure of ABBV-951 in Subjects with Advanced Parkinson's Disease, Role: Investigator, AbbVie, Inc., (09/2024 - 09/2025) Status: Approved
  • A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® for the Treatment of Upper Limb Essential Tremor. Protocol: M21-471, Role: Investigational Pharmacist, AbbVie, Inc., (09/2024 - 09/2025) Status: Approved
  • Implementation of Integrated HIV Prevention and Care Program in Community Pharmacies, Role: Investigator, National Association of Chain Drug Stores Foundation, (11/2023) Status: Approved
  • Implementation of integrated HIV prevention and care programs among Black and Latinx community pharmacy clients, Role: Co-Investigator, National Association of Chain Drug Stores Foundation, (04/2023 - 12/2026) Status: Awarded
  • A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients. Protocol: M15-736, Role: Investigator, AbbVie, Inc., (02/2021 - 02/2022) Status: Completed